ASXL1 Mutations in AML: Molecular Biomarker for Secondary AML?

被引：0
|
作者：
Hsu, Jingmei [1 ]
Kumar, Anita J. [1 ]
Carroll, Martin P. [1 ]
Frey, Noelle V. [1 ]
Shah, Nirav N. [1 ,2 ]
Jianhua, Zhao [3 ]
Hexner, Elizabeth O. [1 ]
Loren, Alison W. [1 ]
Mangan, James K. [1 ]
Perl, Alexander E. [1 ]
Porter, David [1 ]
Morrissette, Jennifer [3 ]
Luger, Selina M. [1 ]
机构：
[1] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA
[2] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA
[3] Hosp Univ Penn, Philadelphia, PA 19104 USA
来源：
BLOOD | 2014年 / 124卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [1] ASXL1 Mutations in AML: Molecular Biomarker for Secondary AML?
    Hsu, Jingmei
    Kumar, Anita
    Carroll, Martin
    Frey, Noelle
    Shah, Nirav
    Zhao, Jianhua
    Hexner, Elizabeth
    Loren, Alison
    Perl, Alexander
    Porter, David
    Morrissette, Jennifer
    Luger, Selina
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2015, 15 : S195 - S195
  • [2] ASXL1 Mutations in AML are Associated Mainly with s-AML and Specific Cytogenetic Findings
    Kakosaiou, K.
    Pagoni, M.
    Daraki, A.
    Apostolou, P.
    Ioannidou, A.
    Zachaki, S.
    Vlachadami, I.
    Marinakis, T.
    Giatra, C.
    Vasilatou, D.
    Sambani, C.
    Pappa, V.
    Manola, K. N.
    ANNALS OF HEMATOLOGY, 2017, 96 : S58 - S58
  • [3] ASXL1 MUTATIONS IN AML ARE ASSOCIATED WITH SPECIFIC CLINICAL AND CYTOGENETIC CHARACTERISTICS
    Kakosaiou, K.
    Panitsas, F.
    Ioannidou, A.
    Pagoni, M.
    Apostolou, P.
    Daraki, A.
    Vlachadami, I.
    Marinakis, T.
    Giatra, C.
    Vasilatou, D.
    Sambani, C.
    Pappa, V.
    Manola, K.
    HAEMATOLOGICA, 2017, 102 : 367 - 368
  • [4] ASXL1 mutations in AML are associated with specific clinical and cytogenetic characteristics
    Kakosaiou, Katerina
    Panitsas, Fotios
    Daraki, Aggeliki
    Pagoni, Maria
    Apostolou, Paraskevi
    Ioannidou, Agapi
    Vlachadami, Ioanna
    Marinakis, Theodoros
    Giatra, Chara
    Vasilatou, Diamantina
    Sambani, Constantina
    Pappa, Vassiliki
    Manola, Kalliopi N.
    LEUKEMIA & LYMPHOMA, 2018, 59 (10) : 2439 - 2446
  • [5] MUTATIONS OF ASXL1 GENE IN PATIENTS WITH AML WITH AN INTERMEDIATE-RISK CYTOGENETIC PROFILE
    Markova, J.
    Michkova, P.
    Maaloufova, J. Soukupova
    Soukup, P.
    Salek, C.
    Brezinova, J.
    Michalova, K.
    Cetkovsky, P.
    Schwarz, J.
    HAEMATOLOGICA, 2014, 99 : 558 - 559
  • [6] ASXL1 mutations are frequent in de novo AML with trisomy 8 and confer an unfavorable prognosis
    Zong, Xiangping
    Yao, Hong
    Wen, Lijun
    Ma, Liang
    Wang, Qinrong
    Yang, Zhiluo
    Zhang, Tongtong
    Chen, Suning
    Wu Depei
    LEUKEMIA & LYMPHOMA, 2017, 58 (01) : 204 - 206
  • [7] ASXL1 mutations in primary and secondary myelofibrosis
    Ricci, Clara
    Spinelli, Orietta
    Salmoiraghi, Silvia
    Finazzi, Guido
    Carobbio, Alessandra
    Rambaldi, Alessandro
    BRITISH JOURNAL OF HAEMATOLOGY, 2012, 156 (03) : 404 - 407
  • [8] The role of ASXL1 mutations and ASXL1 CircRNAs in cancer
    Jafarbeik-Iravani, Narges
    Kolahdozan, Sara
    Esmaeili, Rezvan
    BIOMARKERS, 2024, 29 (01) : 1 - 6
  • [9] Prognostic Effect of ASXL1 Mutations in Patients with MDS and Secondary AML Following MDS After Allogeneic Hematopoietic Stem Cell Transplantation
    Koenecke, Christian
    Thol, Felicitas
    Loeffeld, Patrick
    Buchholz, Stefanie
    Stadler, Michael
    Goehring, Gudrun
    Dammann, Elke
    Kleine, Moritz
    Brauns, Wiebke
    Hallensleben, Michael
    Schmidtke, Joerg
    Schlegelberger, Brigitte
    Krauter, Juergen
    Ganser, Arnold
    Heuser, Michael
    BLOOD, 2011, 118 (21) : 744 - 745
  • [10] ASXL1 exon 12 mutations are frequent in AML with intermediate risk karyotype and are independently associated with an adverse outcome
    S Schnittger
    C Eder
    S Jeromin
    T Alpermann
    A Fasan
    V Grossmann
    A Kohlmann
    T Illig
    N Klopp
    H-E Wichmann
    K-A Kreuzer
    C Schmid
    P Staib
    R Peceny
    N Schmitz
    W Kern
    C Haferlach
    T Haferlach
    Leukemia, 2013, 27 : 82 - 91
12345